News
DXCM
116.64
+0.49%
0.57
DexCom's (DXCM) G6 CGM System Combines With AID in Netherlands
NASDAQ · 1d ago
Dexcom expands AID partnership into the Netherlands
Seeking Alpha · 2d ago
Dexcom Showcases Expanded Focus on Type 2 Diabetes at ADA Conference
Dexcom will present data on Dexcom CGM use among people with Type 2 diabetes at the American Diabetes Association conference. The company is the global leader in real-time continuous glucose monitoring for people with diabetes. Dexcom will also showcase the launch of the Omnipod 5 Automated Insulin Delivery System with Dexcom G7.
Benzinga · 2d ago
Wells Fargo Remains a Buy on Dexcom (DXCM)
TipRanks · 2d ago
Dexcom Showcases Extensive Clinical Data at ADA 2024 Demonstrating the Benefit of Dexcom CGM Use Among People With Type 2 Diabetes
Dexcom will present data on Dexcom CGM use among people with Type 2 diabetes at the American Diabetes Association conference. The company will also showcase the launch of the Omnipod 5 Automated Insulin Delivery System with Dexcom G7. Dexcom is the global leader in real-time continuous glucose monitoring for people with diabetes.
Barchart · 2d ago
TANDEM DIABETES CARE- ON MAY 22, CO, DEXCOM ENTERED AMENDED & RESTATED DEVELOPMENT AGREEMENT TO ORIGINAL DEVELOPMENT AGREEMENT, DATED NOV 20, 2020
Reuters · 3d ago
TANDEM DIABETES CARE - AGREEMENT INCORPORATES INTEGRATION OF CO'S SIGI INSULIN PUMP WITH DEXCOM’S G7 CGM DEVICE, EXTENDS TERM FOR PERIOD OF 5 YEARS
Reuters · 3d ago
Here's How Much $1000 Invested In DexCom 5 Years Ago Would Be Worth Today
DexCom has outperformed the market over the past 5 years by 12.09%. The company has an average annual return of 25.32%. If an investor bought $1000 of DXCM stock 5 years ago, it would be worth $2,994.48 today.
Benzinga · 4d ago
Validea Detailed Fundamental Analysis - DXCM
NASDAQ · 5d ago
Dexcom’s Strong Market Position and Innovative Product Pipeline Bolster Buy Rating
TipRanks · 5d ago
Asensus Surgical (ASXC) Inks a Merger Agreement With KARL STORZ
NASDAQ · 5d ago
Reasons to Retain DexCom (DXCM) Stock in Your Portfolio for Now
NASDAQ · 5d ago
Weekly Report: what happened at DXCM last week (0610-0614)?
Weekly Report · 5d ago
What's New In the Consumer Tech World Last Week? News That You Should Know (June 9-June 15, 2024)
Mark Cuban thinks the U.S. Government's efforts to regulate artificial intelligence will give the lead to Chinese companies. The billionaire entrepreneur says Chinese companies will dominate the field of AI in the future. Cuban believes China will lead in the development of large-language AI models.
Benzinga · 5d ago
DexCom Insiders Sell US$18m Of Stock, Possibly Signalling Caution
DexCom, Inc. Insiders sold US$221k worth of shares in the last year. The biggest insider sale was by the Executive Chairman of DexCom, Kevin Sayer, for US$4.6m. DexCom owns 0.4% of the company. The company has seen significant insider selling over the past year. Insiders didn't buy any shares in DexCom over the last 12 months. It is good to see that DexCom insiders are selling shares at a lower price.
Simply Wall St · 6d ago
Noteworthy Friday Option Activity: CCL, DXCM, DLTR
NASDAQ · 06/14 17:56
Analysts Have Conflicting Sentiments on These Healthcare Companies: Dexcom (DXCM), R1 RCM (RCM) and Vertex Pharmaceuticals (VRTX)
TipRanks · 06/14 06:52
Peering Into DexCom's Recent Short Interest
DexCom's short percent of float has fallen 29.84% since its last report. The company has 7.78 million shares sold short. Short interest is the number of shares that have been sold short but have not yet been covered. Short selling is when a trader sells shares of a company in the hope the price will fall.
Benzinga · 06/11 18:00
Analysts Offer Insights on Healthcare Companies: Teladoc (TDOC) and Dexcom (DXCM)
TipRanks · 06/11 09:30
FOCUS-Olympic athletes turn to diabetes tech in pursuit of medals
Olympic athletes turn to diabetes tech in pursuit of medals to track blood glucose levels. Continuous glucose monitors or CGMs were developed for use by diabetes patients. Their makers Abbott and Dexcom see opportunities in sports and wellness. The CGM market is already worth billions of dollars. There is no proof the technology can boost athletic performance.
Reuters · 06/10 13:40
More
Webull provides a variety of real-time DXCM stock news. You can receive the latest news about Dexcom Inc through multiple platforms. This information may help you make smarter investment decisions.
About DXCM
DexCom, Inc. is a medical device company. The Company enables people to take real-time control of health through continuous glucose monitoring (CGM) systems. The Company is engaged in diabetes care technology. Based on the needs of users, caregivers, and providers, the Company works to simplify and improve diabetes management around the world. The Company is primarily focused on the design, development, and commercialization of CGM, systems for the management of diabetes by patients, caregivers, and clinicians around the world. Its products include Dexcom G6, Dexcom G7, Dexcom Stelo, Dexcom Share, Dexcom Real-Time API, and Dexcom ONE. Dexcom G6 is its integrated continuous glucose monitoring system (iCGM). Dexcom Stelo is designed specifically for people with type II diabetes who do not use insulin and are not at risk for hypoglycemia. The Dexcom Share remote monitoring system, offered for use with any Dexcom system, uses an app on the patient’s compatible mobile device.